The delivery system can be used for pharmaceutical, biopharmaceutical, medical foods, and nutraceutical products. In addition to the existing New Zealand patent, this patent covers the company’s multi-phase, multi-compartment delivery system used to enable the development of multi-compartment, multi-phase delivery forms (two-piece capsule based) of combination products that have compatibility, formulation, or targeted delivery obstacles.
Innercap Technologies claimed that the delivery system and combinations covered by the patent have the ability to deliver therapeutic entities that have never been combined previously and now can be administered together, via an oral, implanted, or suppository capsule, in the most advantageous pharmacokinetic profile, utilizing different physical phases.
The technology can therefore be used to enable capsule administration of compounds that are not normally administered as a combination product. The efficacy, safety, and side-effect profiles of drugs can be substantially improved using this delivery technology. It will also provide very significant quality-of-life improvements for patients and substantial economic savings for hard-pressed healthcare systems.
Fred Miller, CEO of Innercap, said: “Innercap’s multi-phase, multi-compartment technology has been commercially manufactured and validated in several products, demonstrating that Innercap’s delivery system creates real value to consumers and branded manufacturers,” reported the website.